Fulgent Genetics, Inc. (NASDAQ:FLGT) Investors Are Less Pessimistic Than Expected
Those Who Invested in Fulgent Genetics (NASDAQ:FLGT) Five Years Ago Are up 107%
How Much Upside Is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
Express News | Fulgent Genetics Inc : UBS Raises Target Price to $27 From $25
Fulgent Genetics, Inc. (NASDAQ:FLGT) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Fulgent Genetics Second Quarter 2024 Earnings: Beats Expectations
Fulgent Genetics Swings to Q2 Earnings, Revenue Rises
Fulgent Genetics | 10-Q: Q2 2024 Earnings Report
Fulgent Genetics Releases Updated Investor Presentation
Express News | Fulgent Genetics Expect 2024 Core Revenue Of Approximately $280M, With Non-GAAP Loss Improvement From Approximately ($1.05) Per Share To Approximately ($0.30) Per Share, Compared To Consensus Of $280.18M And $(0.92)/Share
Express News | Fulgent Genetics: Sees FY Non-Gaap Loss Improvement From About Loss of $1.05 per Share to About Loss of $0.30 per Share
Fulgent Genetics Reiterates Full Yr 2024 Core Rev Guidance of $280 M >FLGT
Express News | Fulgent Genetics Q2 2024 Adj. EPS $0.15 Beats $(0.30) Estimate, Sales $71.028M Beat $69.066M Estimate
Earnings Flash (FLGT) FULGENT GENETICS Posts Q2 Revenue $71M, Vs. Street Est of $69.1M
Express News | Fulgent Genetics Q2 Operating Expenses USD 45.397 Million
Express News | Fulgent Genetics Q2 Revenue USD 71.028 Million
Express News | Fulgent Genetics Q2 Operating Income USD -18.906 Million
Express News | Fulgent Genetics Q2 Pretax Profit USD -11.214 Million
Express News | Fulgent Genetics Q2 Gross Profit USD 26.491 Million
Express News | Fulgent Genetics Q2 Core Revenue USD 70.2 Million